Drugs / ETV monohydrate
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05123599 Background | Dec 2021 → Jul 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETV monohydrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05123599 ↗ |
| Known as | Entecavir monohydrate | “NA (either Entecavir monohydrate \[ETV\], Tenofovir disoproxil or Tenofovir alafemide \[TAF\]) oral tablets once daily (qd)” NCT05123599 ↗ |
| Route | Oral | “administered orally” NCT05123599 ↗ |